Bellerophon Therapeutics, Inc.: key financial figures for fiscal year 2022 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Net Income/Loss (FY2022)
- -$19.8M
- Total Assets (FY2022)
- $7.9M
- Total Equity (FY2022)
- $2.5M
- Cash Flows from Operating Activities (FY2022)
- -$17.8M
Source: Bellerophon Therapeutics, Inc. 10-K filing (FY2022). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
